Literature DB >> 7677445

Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study.

M A van Leeuwen1, J Westra, P C Limburg, P L van Riel, M H van Rijswijk.   

Abstract

OBJECTIVE: To evaluate the clinical significance of interleukin-6 (IL-6) measurements in relation to laboratory and clinical measures of disease activity and radiological progression in early rheumatoid arthritis (RA).
METHODS: A prospective study was performed in 51 patients with early RA during the first three years of the disease, with monthly clinical and laboratory assessments and biannual radiographs of the hands and feet. IL-6 was measured by enzyme linked immunosorbent assay (ELISA). Cross sectional (n = 51) and longitudinal (n = 20) correlations between plasma IL-6 concentrations and values of C reactive protein (CRP), serum amyloid A protein (SAA), erythrocyte sedimentation rate (ESR), haemoglobin (Hb), platelets, and joint scores were calculated, and correlations made between time integrated values of IL-6, CRP and ESR, and radiological progression over three years (n = 20).
RESULTS: Significant correlations were found between IL-6 and the acute phase response and platelets, but variable results were obtained for the correlation between IL-6 and Hb. In contrast to a significant correlation between time integrated values of CRP or ESR and radiological progression, time integrated values of IL-6 did not correlate with radiological progression over three years follow up.
CONCLUSION: The course of disease activity and the radiological progression of joint damage are better reflected by CRP, SAA, and ESR values than by plasma IL-6 concentrations, particularly in stages of low disease activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7677445      PMCID: PMC1009966          DOI: 10.1136/ard.54.8.674

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

Review 1.  Progress in understanding the pathogenesis of the anemia of chronic disease.

Authors:  R T Means; S B Krantz
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

2.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

3.  Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis.

Authors:  P A Guerne; B L Zuraw; J H Vaughan; D A Carson; M Lotz
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

4.  How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis?

Authors:  J T Sharp; D Y Young; G B Bluhm; A Brook; A C Brower; M Corbett; J L Decker; H K Genant; J P Gofton; N Goodman
Journal:  Arthritis Rheum       Date:  1985-12

5.  Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis.

Authors:  B Dasgupta; M Corkill; B Kirkham; T Gibson; G Panayi
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 6.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

7.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

8.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.

Authors:  F de Benedetti; M Massa; P Robbioni; A Ravelli; G R Burgio; A Martini
Journal:  Arthritis Rheum       Date:  1991-09

9.  Elevated serum interleukin-6 levels in patients with reactive thrombocytosis.

Authors:  C W Hollen; J Henthorn; J A Koziol; S A Burstein
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

10.  Cytokine inter-relationships and their association with disease activity in arthritis.

Authors:  I Holt; R G Cooper; J Denton; A Meager; S J Hopkins
Journal:  Br J Rheumatol       Date:  1992-11
View more
  16 in total

1.  Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease.

Authors:  C Schulte; H Goebell; H D Röher; K M Schulte
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

Review 2.  Neuroendocrine effects of stress on immunity in the elderly: implications for inflammatory disease.

Authors:  Kathi L Heffner
Journal:  Immunol Allergy Clin North Am       Date:  2011-02       Impact factor: 3.479

3.  Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: relationship to systematic vasculitis and microvascular capillaroscopic abnormalities.

Authors:  A Kuryliszyn-Moskal
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis.

Authors:  A S de Hooge; F A van De Loo; O J Arntz; W B van Den Berg
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

5.  Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice.

Authors:  F A van de Loo; S Kuiper; F H van Enckevort; O J Arntz; W B van den Berg
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

6.  Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.

Authors:  Ayse Acar; Savas Guzel; Banu Sarifakioglu; Eda Celik Guzel; Aliye Yildirim Guzelant; Ceyda Karadag; Lebriz Kiziler
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

7.  Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue.

Authors:  Mary C Davis; Alex J Zautra; Jarred Younger; Sarosh J Motivala; Jeanne Attrep; Michael R Irwin
Journal:  Brain Behav Immun       Date:  2007-08-15       Impact factor: 7.217

8.  Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.

Authors:  K Migita; Y Izumi; Y Jiuchi; H Kozuru; C Kawahara; M Izumi; T Sakai; M Nakamura; S Motokawa; T Nakamura; A Kawakami
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

9.  The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.

Authors:  Hilde Berner Hammer; Magne K Fagerhol; Tale Norbye Wien; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2011-10-26       Impact factor: 5.156

Review 10.  Biomarkers in Rheumatoid Arthritis.

Authors:  Samantha C Shapiro
Journal:  Cureus       Date:  2021-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.